All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub
Brought to you by Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2019 | Could the first-in-class anti-CD47 antibody HU5F9-G4 be a promising treatment strategy?

By Emily Smith,David Sallman

Share:

Featured:

David SallmanDavid Sallman

Oct 16, 2020

At the 24th Congress of the European Hematology Association (EHA), David Sallman from the Moffitt Cancer Center, Tampa, US, discusses if the first-in-class anti-CD47 antibody HU5F9-G4 (5F9) could be a promising treatment strategy for patients with acute myeloid leukemia (AML).
 
5F9 is a first-in-class IgG4 antibody that targets CD47 to enable phagocytosis. David Sallman discusses the initial results from the phase Ib trial investigating 5F9 alone, or with azacitidine, in patients with high-risk AML and myelodysplastic syndrome (MDS). The early data indicate that 5F9 is well-tolerated, with promising activity in patients with AML/MDS, and that adding 5F9 to cytotoxic agents may be a promising treatment strategy.

Could the first-in-class anti-CD47 antibody HU5F9-G4 be a promising treatment strategy?

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2019Antibody therapyEuropean Hematology Association

Newsletter

Subscribe to get the best content delivered to your inbox